Evidence map›Paper›PMID 40938562›Full record

ArticleBreast cancer (Tokyo, Japan)2026

C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.

Mio Yamaguchi-Tanaka, Yui Kurihara, Kiyoshi Takagi, Ai Sato, Iori Yasuda, Yuto Yamazaki, Minoru Miyashita, Takashi Suzuki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mio Yamaguchi-Tanaka *Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi-Ken, 980-8575, Japan.
Yui Kurihara *Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi-Ken, 980-8575, Japan.
Kiyoshi TakagiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi-Ken, 980-8575, Japan. kiyoshi.takagi.b7@tohoku.ac.jp.ORCID http://orcid.org/0000-0002-5200-6514
Ai SatoDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi-Ken, 980-8575, Japan.
Iori YasudaDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi-Ken, 980-8575, Japan.
Yuto YamazakiDepartment of Pathology, Tohoku University Hospital, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan.
Minoru MiyashitaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
Takashi SuzukiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi-Ken, 980-8575, Japan.

Funding

Japan Society for the Promotion of Science 19K09065Japan Society for the Promotion of Science 23K08065Japan Society for the Promotion of Science 23K19493Japan Society for the Promotion of Science 24K11736
6 · The paper itself

Abstract

backgroundC-type lectin-like domain family 2 (CLEC2D), a transmembrane protein, is a ligand for the inhibitory receptor CD161, which is expressed in several types of immune cells. CLEC2D expressed on cancer cells suppresses antitumor effect of these cells by interacting with CD161 in human malignancies. However, its clinical significance in breast cancer and its direct biological role in cancer cells remain largely unclear.

methodsIn this study, we immunolocalized CLEC2D in 174 breast cancer tissues and correlated its immunoreactivity with clinicopathological parameters and clinical outcomes. Additionally, we conducted in vitro assays to examine the effects of CLEC2D on the proliferation and migration of breast cancer cell lines.

resultsCLEC2D immunoreactivity was predominantly detected in the cytoplasm of breast cancer cells and was associated with increased proliferation and invasion, as well as poor clinical outcomes especially in those who had received chemotherapy. In vitro experiments demonstrated that the knockdown of CLEC2D significantly suppressed the proliferation and migration of MCF-7, MDA-MB-231, T-47D breast cancer cells.

conclusionWe therefore concluded that CLED2D directly promoted breast cancer cell proliferation and migration independently of immune cells and served as a poor prognostic factor in breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsLectins, C-TypeReceptors, MitogenAdultAgedCell Line, TumorCell MovementCell ProliferationFemaleHumansMCF-7 CellsMiddle AgedNeoplasm InvasivenessPrognosisReceptors, Cell SurfaceBiomarkers, TumorCLEC2D protein, humanLectins, C-TypeReceptors, Cell SurfaceReceptors, MitogenBreast cancerC-type lectin-like domain family 2 (CLEC2D)ImmunohistochemistryPrognostic factorTumor microenvironment

Identifiers

PMID40938562
PMCPMC12789214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.